Sage Journals: Discover world-class research

Abstract

Cardiovascular disease is very common in women. It is still under diagnosed and under treated. Many women are not having their risk factors for cardiovascular disease properly addressed. Many healthcare professionals are uncertain about the role of hormones in cardiovascular disease. This article gives an overview of the most important risk factors for cardiovascular disease and how to manage those risk factors appropriately, based on the available evidence.

Keywords

Estrogen heart disease hormone replacement therapy menopause

Get full access to this article

View all access options for this article.

References

Tandon

Mahajan

Sharma

et al.

Prevalence of cardiovascular risk factors in postmenopausal women: a rural study. J Midlife Health 2010; 1: 26–29.

www.bhf.org.uk/research/heart-statistics .

Harvey

Coffman

Miller

. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. Womens Health (Lond) 2015; 11: 239–257.

Anand

Islam

Rosengren

et al.

Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932–940.

Mendelsohn

Karas

. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583–1587.

Kearney

Whelton

Reynolds

et al.

Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.

Lloyd-Sherlock

Beard

Minicuci

et al.

Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol 2014; 43: 116–128.

Lewington

Clarke

Qizilbash

et al.

Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

Staessen

Bulpitt

Fagard

et al.

The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: 427–433.

10.

Vasan

Larson

Leip

et al.

Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297.

11.

WHO Global Infobase, https://apps.who.int/infobase/Indicators.aspx (accessed 13 December 2017).

12.

Ossewaarde

Bots

Verbeek

et al.

Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16: 556–562.

13.

van der Schouw

van der Graaf

Steyerberg

et al.

Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714–718.

14.

Lokkegaard

Jovanovic

Heitmann

et al.

The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006; 53: 226–233.

15.

Atsma

Bartelink

Grobbee

et al.

Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265–279.

16.

Rossouw

Anderson

Prentice

et al.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.

17.

Menopause: diagnosis and management. NICE, 2015. www.nice.org.uk/guidance/ng23.

18.

Baber RJ, Panay N and Fenton A. The IMS Writing Group 2016 IMS Recommendations on women's midlife health and menopause hormone therapy, Climacteric 2016; 19(2): 109–150.

19.

Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 2017; 20(4): 306–312.

20.

Franco

Muka

Colpani

et al.

Vasomotor symptoms in women and cardiovascular risk markers: systematic review and meta-analysis. Maturitas 2015; 81: 353–361.

21.

Hypertension: management of hypertension in adults in primary care. NICE Clinical Guideline (August 2011), www.nice.org.uk/guidance/cg127.

22.

Mancia G, Fagard R, Narkiewicz K, et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. Blood Press 2014; 23(1): 3–16.

23.

Lloyd-Sherlock

Beard

Minicuci

et al.

Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol 2014; 43: 116–128.

24.

Reiner

Catapano

et al.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818.

25.

Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE 2016, www.nice.org.uk/guidance/cg181.

26.

Maclaren

Stevenson

. Primary prevention of cardiovascular disease with HRT. Women’s Health 2012; 8: 63–74.

27.

Collins

Webb

de Villiers

et al.

2016) Cardiovascular risk assessment in women – an update. Climacteric 2016; 19: 329–336.

28.

Lokkegaard

Jovanovic

Heitmann

et al.

The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006; 53: 226–233.

29.

POI Guideline Development Group. Management of women with premature ovarian insufficiency. 2015, www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx.

30.

Hamoda

. British Menopause Society and Women’s Health Concern. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post Reprod Health 2017; 23: 22–35.

31.

L’Hermite

. HRT optimization, using transdermal estradiol plus micronize progesterone, a safer HRT. Climacteric 2013; 16(Suppl. 1): 44–53.

32.

Santen

. Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. Menopause 2017; 24: 589–595.

33.

Hulley

Grady

Bush

et al.

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613.

34.

Rossouw

Prentice

Manson

et al.

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477.

35.

Vitale

Mercuro

Cerquetani

et al.

Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008; 28: 348–352.

36.

Boardman

Hartley

Eisinga

et al.

Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 3: CD002229.

37.

Mikkola

Tuomikoski

Lyytinen

et al.

Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015; 22: 976–983.

38.

Schierbeck

Rejnmark

Tofteng

et al.

Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.

39.

Hodis

Mack

Henderson

et al.

Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016; 374: 1221–1231.

40.

Lobo

Pickar

Stevenson

et al.

Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 2016; 254: 282–290.

41.

Mikkola

et al.

Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015; 100: 4588–4594.

42.

Wingrove

Garr

Godsland

et al.

17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998; 1406: 169–174.

43.

Stanczyk

Hapgood

Winer

et al.

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013; 34: 171–208.

44.

Honisett

Pang

Stojanovska

et al.

Progesterone does not influence vascular function in postmenopausal women. J Hypertens 2003; 21: 1145–1149.

45.

Boschitsch

Mayerhofer

Magometschnigg

. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010; 13: 307–313.

Menopause and cardiovascular disease

Abstract

Keywords

Get full access to this article

References